gene therapy stock poised for catalysts By Investing.com
Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a biopharmaceutical company with a market capitalization of $252 million specializing in gene therapies for rare cardiac diseases and Alzheimer’s, has garnered attention from analysts for its promising pipeline and upcoming catalysts. According to InvestingPro data, the company maintains a “FAIR” overall financial health score, suggesting a balanced risk-reward profile despite its early-stage status. Founded in 2017 and based in New York City, Lexeo has positioned itself at the forefront of genetic medicine, leveraging its proprietary AAVrh10-based gene therapies to address significant unmet medical needs.
Company Overview
Lexeo Therapeutics focuses on developing precision medicine solutions for…
